Bobak R. Azamian

CEO Bobak R. Azamian sells 10,000 shares at $61.55 avg under 10b5-1 plan; holds 848.0K post-sale.

Bobak R. Azamian, President/CEO and Board Chair of Tars Pharmaceuticals (TARS), executed 2 separate sales totaling 10,000 shares for $615,488.26 at blended average price $61.55 on 2026-06-17. The transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-09, so execution was scheduled rather than discretionary. His post-transaction holdings of 847,991 shares represent a 1.2% reduction from prior holdings. At the same-ticker level, Azamian's 5 prior TARS sales show mixed post-sale price action (30-day returns ranging from -2.4% to +3.9%, 90-day returns from -18.0% to -6.6%), with no clear directional pattern. The company reported quarterly revenue of $162,054,000.00 but remains unprofitable with net income of $-6,967,000.00 in the latest quarter; full-year profitability remains negative. Stock is currently trading at $63.56, down 25.4% from the 52-week high of $85.25.

Tarsus CEO Azamian sells 34,603 shares over 3 days for $2.4M at $68.34 avg, cutting stake 50.9%; stock currently $66.75.

Azamian Bobak R., President/CEO and Board Chair, executed 3 separate sales totaling 34,603 shares for $2,364,903.81 at a blended average price of $68.34 on March 17–19, 2026, reducing his holdings by 50.9% from 68,024 shares to 33,421 shares post-transaction. The filing warrants attention because the CEO liquidated exactly half his stake during a period when the stock is down 18.0% over 90 days and remains 19.1% below its 52-week high of $82.51, despite a recent 30-day bounce of 6.3%. At the company level, Tarsus is unprofitable (full-year net income was negative, latest quarter shows $-12,585,000) but growing revenue aggressively at 146.7% year-over-year, suggesting execution risk in a growth-stage business. His prior 5 sales at TARS show mixed timing outcomes: 3 of the 5 were well-timed at the 90-day mark, including two consecutive December 2023 sales each showing 90-day gains exceeding +54%, though his most recent March 2025 sale declined 18.0% over 90 days, a near-identical pattern to the current period's 90-day drawdown.

TARS CEO Azamian sold 24,216 shares for $1,163,050.13 across 3 days (Mar 18-20) at blended avg $48.03; reduces stake by 31.1%

CEO Bobak Azamian conducted 3 separate sales totaling 24,216 shares for $1,163,050.13 across March 18–20, reducing his holdings from 77.9K to 53.6K shares (a 31.1% reduction). The transactions occurred at prices ranging from $46.29 to $50.11, with a blended average of $48.03, in a stock currently trading at $49.91 (within the 52-week range of $21.54–$56.94). Notably, his prior trades at TARS showed mixed results: two December 2023 sells generated +17.6% and +15.3% gains over 30 days (and +57.9%, +54.8% over 90 days), while two July 2023 sells resulted in -11.2% to -14.6% declines. The company reports $48.1M in latest-quarter revenue with $-23.4M net income and remains unprofitable, though annual revenue growth stands at +948.6%. The timing pattern across his TARS history suggests inconsistent execution, and this substantial stake reduction warrants monitoring given the company's unprofitable state and the magnitude of the selloff relative to his pre-transaction position.